OSI Pharma says Tarceva patent extended through Nov 2018
OSI Pharmaceuticals Inc. said it received a notice from the U.S. Patent and Trademark Office that the patent for its cancer drug Tarceva has been extended through Nov. 8, 2018
This entry was posted on Tuesday, September 18th, 2007 at 8:52 am and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.